46 results about "Metastatic lesion" patented technology

Methods and compositions for modulating the FGF effect on the sensitivity of malignant and normal cells to anticancer agents are provided. In particular, methods and compositions for inhibiting FGF-induced resistance to a broad spectrum of anticancer agents in solid and soft-tissue tumors, metastatic lesions, leukemia and lymphoma are provided. Preferably, the compositions include at least one FGF inhibitor in combination with a cytotoxic agents, e.g., antimicrotubule agents, topoisomerase I inhibitors, topoisomerase II inhibitors, antimetabolites, mitotic inhibitors, alkylating agents, intercalating agents, agents capable of interfering with a signal transduction pathway (e.g., g., a protein kinase C inhibitor, e.g., an anti-hormone, e.g., an antibody against growth factor receptors), an agent that promotes apoptosis and / or necrosis, and interferon, an interleukin, a tumor necrosis factor, and radiation. In other embodiments, methods and composition for protecting a cell in a subject, from one or more of killing, inhibition of growth or division or other damage caused, e.g., by a cytotoxic agent, are provided. Preferably, the method includes: administering, to the subject, an effective amount of at least one FGF agonist, thereby treating the cell, e.g., protecting or reducing the damage to the dividing cell from said cytotoxic agent.

To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed 79 differentially expressed genes, including 46 that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions of the liver. These results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.

To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed 79 differentially expressed genes, including 46 that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions of the liver. These results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.

To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed many differentially expressed genes, including a large nujber of genes that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions fo the liver. Theses results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic.

Tumor necrosis factor (TNF) is capable of inducing apoptosis by interacting with specific TNF receptors on the surface of cancer cells. Because multiple members of TNF ligand and receptor are present within each superfamily, over 300 different ligand-receptor combinations exist. Activated blood leukocytes produce TNF as part of the immune response to cancer, as well as producing chemokines to attract other leukocytes to the site. A method is disclosed of detecting significant induction of a variety of TNF superfamily subtype and chemokine mRNAs in blood leukocytes when whole blood is exposed to heat-aggregated IgG or anti-T cell receptor antibodies as a model of immune system interactions. Substantial individual-to-individual variation is observed in TNF subtypes and chemokines induced. Since peripheral blood leukocytes are the supply of anti-cancer immune cells, the quantitation of ex vivo inducibility of appropriate TNF ligands and chemokines in blood will be useful in individualized cancer immunotherapy. If the tumor mass is small, such as with early invisible metastatic lesions, appropriate TNF assaults may be sufficient to prevent relapse.

Disclosed herein is the treatment of vision loss in a mammal by transplanting an effective amount of hNT-Neuron cells. The treatment can be accomplished by injecting the cells into the retinal area of the eye. Additionally, the cells can be injected into the visual cortex of the brain. Conditions to be treated are vision loss due to optic nerve damage, including glaucoma, optic nerve sheath meningioma and glioma, Graves' ophthalmopathy, benign or malignant orbital tumors, metastatic lesions, tumors arising from the adjacent paranasal sinuses or middle cranial fossa, giant pituitary adenomas, brain tumors or abscesses, cerebral trauma or hemorrhage, meningitis, arachnoidal adhesions, pseudotumor cerebri, cavernous sinus thrombosis, dural sinus thrombosis, encephalitis, space-occupying brain lesions, severe hypertensive disease or pulmonary emphysema.

A brachytherapy applicator for treatment of metastic lesions in a load bearing region is provided. The applicator comprises an elongate tube body having a proximal and a distal end and defining an open internal area. A fixation element located on an outer portion of the tube allows the applicator to be fixed in position in relation to a target region while delivering a dose of therapeutic radiation. The fixation element can fix the applicator to tissue and / or a stabilization element implanted within a patient. A source of radiation positioned within the elongate body, before, during, or after implantation of the applicator, provides the therapeutic radiation.

We achieved the present invention on the basis of the finding that an excellent therapeutic effect against pancreatic cancer can be obtained by administering an XL-6 inhibitor and an antimetabolite to pancreatic cancer patients. We also found that metastatic lesions from human pancreatic cancer can be reduced and ascites can be eliminated.

To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed 79 differentially expressed genes, including 46 that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions of the liver. These results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.

Tumor necrosis factor (TNF) is capable of inducing apoptosis by interacting with specific TNF receptors on the surface of cancer cells. Because multiple members of TNF ligand and receptor are present within each superfamily, over 300 different ligand-receptor combinations exist. Activated blood leukocytes produce TNF as part of the immune response to cancer, as well as producing chemokines to attract other leukocytes to the site. A method is disclosed of detecting significant induction of a variety of TNF superfamily subtype and chemokine mRNAs in blood leukocytes when whole blood is exposed to heat-aggregated IgG or anti-T cell receptor antibodies as a model of immune system interactions. Substantial individual-to-individual variation is observed in TNF subtypes and chemokines induced. Since peripheral blood leukocytes are the supply of anti-cancer immune cells, the quantitation of ex vivo inducibility of appropriate TNF ligands and chemokines in blood will be useful in individualized cancer immunotherapy. If the tumor mass is small, such as with early invisible metastatic lesions, appropriate TNF assaults may be sufficient to prevent relapse.

The invention relates to a preparation method and application of macrophage membrane bionic bismuth selenide nanoparticles. The preparation problem of macrophage membrane bionic bismuth selenide nanoparticles and the application problem in preparing bionic anti-tumor drugs and photothermal treatment drugs based on cell membrane wrapping can be effectively solved. According to the technical scheme,the surface of hollow bismuth selenide nanoparticles is physically loaded with an anti-tumor drug quercetin, and then the hollow bismuth selenide nanoparticles with the quercetin is co-extruded withcell membrane vesicles obtained by low-permeability lysis solution pyrolysis treatment of cells and homogenization, so as to obtain a pharmaceutical composition of the cell membrane bionic bismuth selenide nanoparticles with a particle size of 120-150nm. The preparation process is simple and feasible; the particle size distribution is uniform; the sensitivity of cancer cell to light and heat is enhanced, and the anti-tumor effect of photothermal therapy is enhanced; the macrophage membrane bionic bismuth selenide nanoparticles have multiple functions such as metastatic lesions targeting capability, CT imaging and the like; and the anti-tumor efficacy of the drug is improved.

To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed many differentially expressed genes, including a large nujber of genes that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions fo the liver. Theses results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic.

We achieved the present invention on the basis of the finding that an excellent therapeutic effect against pancreatic cancer can be obtained by administering an IL-6 inhibitor and an antimetabolite to pancreatic cancer patients. We also found that metastatic lesions from human pancreatic cancer can be reduced and ascites can be eliminated.

The invention discloses a boron-containing compound for BNCT and a preparation method and application thereof, and belongs to the field of medicines. The novel boron-containing compound is obtained through condensation, ammonolysis and cyclization reaction, and is easy to prepare, low in cost, and has good biological properties; the boron-containing compound is better than BPA on uptake, accumulation and reservation of tumour cells, free of any signs of toxicity, and has a good application prospect in BNCT. Moreover, the boron-containing compound is further expected to be a clinical potential positron emission tomography tumor imaging agent after being labeled through radioactive elements, and creates the advantage conditions for diagnosis of malignant tumor, identification of benign and malignant diseases, exploration of systematic metastatic lesions and the like.

Cellular and genetic signatures and methods of using same for subcategorizing stage III melanoma tumors are described herein. The signatures and methods are particularly useful with regard to establishing more distinct criteria on which basis to differentiate stage IIIB and IIIC melanoma patients. Assessment of the cellular and genetic signatures of a melanoma sample using methods described herein yields information on which basis differential survival duration and sensitivity to various cancer therapies can be predicted for a Stage IIIB or Stage IIIC melanoma patients. As described herein, gene expression profiling, determination of mitotic index (MI), and quantification of tumor infiltrating leukocytes (TILs) and CD3+ cells in metastatic lesions may be utilized to predict or assess drug response, drug sensitivity, and clinical outcome in metastatic melanoma patients.

We achieved the present invention on the basis of the finding that an excellent therapeutic effect against pancreatic cancer can be obtained by administering an IL-6 inhibitor and an antimetabolite to pancreatic cancer patients. We also found that metastatic lesions from human pancreatic cancer can be reduced and ascites can be eliminated.

The invention discloses traditional Chinese medicine decoction for treating stomach cancer, belonging to the field of traditional Chinese medicines. The traditional Chinese medicine decoction for treating stomach cancer is prepared from the following bulk drugs by weight: 10 g of frankincense, 10 g of cinnamon, 15 g of selfheal, 15 g of agilawood, 15 g of radix ophiopogonis, 15 g of curcuma zedoary, 15 g of myrrh, 15 g of astragalus membranaceus, 15 g of the root of red-rooted salvia, 15 g of glossy privet fruit, 15 g of schisandra chinensis, 15 g of Chinese angelica, 15 g of root of common peony, 15 g of the rhizome of chuanxiong, 10 g of corydalis tuber, 10 g of rehmannia, 10 g of lucid ganoderma, 10 g of oldenlandia diffusa, 10 g of radix polygonati officinalis, 10 g of moutan bark, 10 g of edible tulip, 10 g of immature bitter orange, 10 g of lithospermum, and 5 g of musk. The traditional Chinese medicine decoction for treating stomach cancer has the effects of supporting body resistance, reinforcing qi, nourishing blood, promoting circulation, removing stasis, clearing heat and removing toxicity and is capable of effectively controlling metastasis of primary lesion and continuous diffusion of metastatic lesion and obviously relieving stomach cancer clinical symptoms; the traditional Chinese medicine decoction for treating stomach cancer has obvious curative effect on treatment of stomach cancer.

The invention provides a method for establishing a mice transplantable breast cancer experimental pulmonary metastasis model. The method comprises the following steps: grinding mice spontaneous breast cancer adenoma in a mesh screen, carrying out centrifugal precipitation, preparing a tumour cell suspension with the cell concentration of (1-2)*107 cell / mL by the use of a nutrient solution, carrying out tail intravenous injection on each mouse by the use of 0.1-0.3mL of the tumour cell suspension, feeding the mice under normal conditions and normally breeding for 25-35 days to finish the pulmonary metastasis model. The injected tumor cells are prepared by grinding genuine C3H mice tumor cells in mice, thus better simulating the in vivo metastasis process. According to the breast cancer experimental metastasis model, tumour cells are directly injected into animal bodies through a tail intravenous injection mode; after the injection, animals are raised under normal conditions without special environment; and after transplantation, it is detected that metastatic lesions are formed in C3H mice lungs through blood circulation. The method provided by the invention has advantages of high incidence rate, short tumour formation time, high incidence rate of metastasis and low cost, etc.

A brachytherapy applicator for treatment of metastic lesions in a load bearing region is provided. The applicator comprises an elongate tube body having a proximal and a distal end and defining an open internal area. A fixation element located on an outer portion of the tube allows the applicator to be fixed in position in relation to a target region while delivering a dose of therapeutic radiation. The fixation element can fix the applicator to tissue and / or a stabilization element implanted within a patient. A source of radiation positioned within the elongate body, before, during, or after implantation of the applicator, provides the therapeutic radiation.

The invention relates to a mouse model with lung metastasis of gastric cancer and an establishment method thereof, and belongs to the technical field of experimental animals. According to the mouse model and the establishment method thereof, BGC-823 and MKN-45 gastric cancer cells are cultured in vitro, and resuspended to a proper concentration with sterile PBS when the cell viability is strong. After the cells are cultured inside the body of immunodeficient NUDE and SCID mice inoculated in immunodeficience through the caudal vein, the mouse model with lung metastasis of gastric cancer is successfully obtained by the identifications including the statistics of surface lung nodules, HE staining and IHC staining. According to the mouse model establishment, needed experimental conditions and operation are simple and convenient, lung metastasis lesions after the experiment are obvious, metastasis efficiency is high, and mice with metastatic lesions have moderate survival cycles. In the evaluation and statistics of the metastasis results, the macroscopic counting of the lung nodules is improved into the microscopic counting of the IHC staining positive cells, thereby obtaining more objective and accurate results. The animal model of tumor metastasis may be widely used in scientific research and teaching.

Disclosed are methods of identifying agents for treating metastatic lesions of colorectal cancer. Also disclosed are methods for treating metastatic lesions of colorectal cancer and preventing metastasis of colorectal cancer.

Compositions and methods for the treatment of fracture and metastatic bone cancer are disclosed.

The invention discloses traditional Chinese medicine composition for treating oral cancer, esophageal cancer, nasopharyngeal carcinoma and gastric cancer and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the raw materials in parts by weight as follows: 1-3 parts of spreading hedyotis herbs, 1-3 parts of barbated skullcup herbs, 1-3 parts of Chinese lobelia herbs, 1-3 parts of Yunnan manyleaf paris rhizomes, 3-5 parts of milkvetch roots, 0.5-1.5 parts of frankincense, 0.5-1.5 parts of myrrh, 1-3 parts of licorice roots, 1-3 parts of honeysuckle flowers, 3-5 parts of snakegourd roots and 0.5-1.5 parts of ganoderma lucidum spore powder. The invention further discloses a preparation method of the traditional Chinese medicine composition as well as a medicine for treating the oral cancer, the esophageal cancer, the nasopharyngeal carcinoma and the gastric cancer. The traditional Chinese medicine composition can effectively control metastasis of primary lesions and continuous diffusion of the metastatic lesions and remarkably alleviate clinical symptoms of the oral cancer, the esophageal cancer, the nasopharyngeal carcinoma and the gastric cancer; the composition has no toxic or side effects, is definite in curative effect, takes effect quickly and is safe to use and convenient to take.

The invention discloses traditional Chinese medicine composition for treating prostatic cancer and intestinal cancer, a preparation method and a medicine comprising the traditional Chinese medicine composition, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the raw materials in parts by weight as follows: 1-3 parts of barbated skullcup herbs, 1-3 parts of giant knotweed rhizomes, 1-3 parts of solidago, 0.5-1.5 parts of coptis chinensis, 1-3 parts of broomjutre sida herbs, 1-3 parts of viscid germander herbs, 1-3 parts of laciniate kalanchoe herbs and 0.05-0.15 parts of musk. The invention further discloses a preparation method of the traditional Chinese medicine composition and a medicine comprising the traditional Chinese medicine composition. The traditional Chinese medicine composition can effectively control metastasis of primary lesions and continuous diffusion of the metastatic lesions and remarkably alleviate clinical symptoms of the prostatic cancer and the intestinal cancer; the composition has no toxic or side effects, can remarkably alleviate pain of a patient, is definite in curative effect, takes effect quickly and is safe to use, controllable in quality and convenient to take.

The evolutionary origin of high-grade serous ovarian carcinoma remains largely unknown. The vast majority of tumor-specific genomic alterations from ovarian cancers are present in fallopian tube STIC lesions (average of 55 sequence alterations per tumor), including those affecting TP53, BRCA1, BRCA2 or PTEN genes. A quantitative evolutionary analysis indicated that tumors of the fallopian tube were the likely precursors of ovarian cancer and could directly give rise to metastatic lesions. These analyses suggest that there may be less than two years between the development of a STIC and the initiation of fallopian tube tumors, ovarian tumors or other metastases. Thus there may be a short window between the development of a STIC and the initiation of ovarian tumors or other metastases, highlighting the importance of the prevention, early detection and therapeutic intervention of this disease.

Methods and compositions for modulating the FGF effect on the sensitivity of malignant and normal cells to anticancer agents are provided. In particular, methods and compositions for inhibiting FGF-induced resistance to a broad spectrum of anticancer agents in solid and soft-tissue tumors, metastatic lesions, leukemia and lymphoma are provided. Preferably, the compositions include at least one FGF inhibitor in combination with a cytotoxic agents, e.g., antimicrotubule agents, topoisomerase I inhibitors, topoisomerase II inhibitors, antimetabolites, mitotic inhibitors, alkylating agents, intercalating agents, agents capable of interfering with a signal transduction pathway (e.g., g., a protein kinase C inhibitor, e.g., an anti-hormone, e.g., an antibody against growth factor receptors), an agent that promotes apoptosis and / or necrosis, an interferon, an interleukin, a tumor necrosis factor, and radiation.In other embodiments, methods and composition for protecting a cell in a subject, from one or more of killing, inhibition of growth or division or other damage caused, e.g., by a cytotoxic agent, are provided. Preferably, the method includes: administering, to the subject, an effective amount of at least one FGF agonist, thereby treating the cell, e.g., protecting or reducing the damage to the dividing cell from said cytotoxic agent.

Primary and metastatic lesions are distinguished in the treatment plan. A radiotherapy system according to an embodiment includes processing circuitry. The processing circuitry specifies at least onetumor area in a medical image of a patient, and outputs classification result information including a result of classifying this / these tumor area(s) as either a primary lesion or a metastatic lesion based on an image feature amount of this / these tumor area (s).

The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing Protocadherin 7 and Connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of Protocadherin 7 and / or Connexin 43 expression in cancer cells reduce progression of brain metastases. It is further based on the discovery that treatment with gap junction inhibitors tonabersat and meclofenamate inhibited progression of brain metastatic lesions and enhanced the anti-cancer activity of the conventional chemotherapeutic agent, carboplatin.

The invention relates to the technical field of biological medicines, in particular to an anti-tumor composition, an application thereof and an anti-tumor medicine comprising the anti-tumor composition. The anti-tumor composition comprises a cis-platinum nano preparation and an immune checkpoint inhibitor. According to the anti-tumor composition provided by the invention, the cis-platinum nano preparation and the immune checkpoint inhibitor are combined for application, so that the sensitivity of malignant tumors to radiotherapy can be obviously improved, the telecentric effect of radiotherapy of malignant tumors in middle and advanced stages is effectively improved, and a systematic inhibition effect on metastatic tumors is achieved through the telecentric effect of local radiotherapy. Synergistic radiotherapy can effectively enhance the treatment effect on multiple metastatic lesions of the whole body of a patient suffering from middle and advanced stage cancer.